Tags

Type your tag names separated by a space and hit enter

A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
Arthritis Rheum. 2006 Dec; 54(12):3939-44.AR

Abstract

OBJECTIVE

To investigate the presence and clinical significance of autoantibodies against the interferon-inducible gene IFI16 in systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and other autoimmune diseases.

METHODS

Immunohistochemical analysis was used to evaluate the expression of IFI16 in skin biopsy specimens obtained from patients with SSc and patients with SLE. Levels of antibodies against IFI16 in sera from 82 patients with SSc and 100 patients with SLE were determined by enzyme-linked immunosorbent assay. Other autoimmune diseases such as primary Sjögren's syndrome (SS), rheumatoid arthritis (RA), chronic urticaria, and hepatitis C virus (HCV) infection were also examined.

RESULTS

Expression of IFI16 was greatly increased and was ubiquitous in all layers of the epidermis and in the dermal inflammatory infiltrates of lesional skin from both patients with SLE and patients with SSc. Patients with SLE, those with primary SS, and those with SSc exhibited significantly higher anti-IFI16 IgG antibody levels compared with normal controls (for SLE, P < 0.002; for primary SS, P < 0.001; for SSc, P < 0.0005). Anti-IFI16 titers above the ninety-fifth percentile for control subjects were observed in 26% of the patients with SLE, 50% of those with primary SS, and 21% of those with SSc (28% of patients with limited cutaneous SSc [lcSSc] versus 4% of patients with diffuse cutaneous SSc [dcSSc]). In contrast, the prevalence of anti-IFI16 was 4% in patients with RA, 5% in those with chronic urticaria, and 13% in those with HCV infection.

CONCLUSION

The results of this study provide evidence that an IFN-inducible gene, IFI16, may be involved in the pathophysiologic mechanisms of connective tissue disorders such as SSc. Moreover, a strict correlation with lcSSc was also demonstrated, thus providing a novel tool in the differential diagnosis of lcSSc from dcSSc.

Authors+Show Affiliations

Medical School of Turin, Turin, and Medical School of Piemonte Orientale, Novara, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17133607

Citation

Mondini, Michele, et al. "A Novel Autoantigen to Differentiate Limited Cutaneous Systemic Sclerosis From Diffuse Cutaneous Systemic Sclerosis: the Interferon-inducible Gene IFI16." Arthritis and Rheumatism, vol. 54, no. 12, 2006, pp. 3939-44.
Mondini M, Vidali M, De Andrea M, et al. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. Arthritis Rheum. 2006;54(12):3939-44.
Mondini, M., Vidali, M., De Andrea, M., Azzimonti, B., Airò, P., D'Ambrosio, R., Riboldi, P., Meroni, P. L., Albano, E., Shoenfeld, Y., Gariglio, M., & Landolfo, S. (2006). A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. Arthritis and Rheumatism, 54(12), 3939-44.
Mondini M, et al. A Novel Autoantigen to Differentiate Limited Cutaneous Systemic Sclerosis From Diffuse Cutaneous Systemic Sclerosis: the Interferon-inducible Gene IFI16. Arthritis Rheum. 2006;54(12):3939-44. PubMed PMID: 17133607.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. AU - Mondini,Michele, AU - Vidali,Matteo, AU - De Andrea,Marco, AU - Azzimonti,Barbara, AU - Airò,Paolo, AU - D'Ambrosio,Roberta, AU - Riboldi,Piersandro, AU - Meroni,Pier Luigi, AU - Albano,Emanuele, AU - Shoenfeld,Yehuda, AU - Gariglio,Marisa, AU - Landolfo,Santo, PY - 2006/11/30/pubmed PY - 2007/2/7/medline PY - 2006/11/30/entrez SP - 3939 EP - 44 JF - Arthritis and rheumatism JO - Arthritis Rheum VL - 54 IS - 12 N2 - OBJECTIVE: To investigate the presence and clinical significance of autoantibodies against the interferon-inducible gene IFI16 in systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and other autoimmune diseases. METHODS: Immunohistochemical analysis was used to evaluate the expression of IFI16 in skin biopsy specimens obtained from patients with SSc and patients with SLE. Levels of antibodies against IFI16 in sera from 82 patients with SSc and 100 patients with SLE were determined by enzyme-linked immunosorbent assay. Other autoimmune diseases such as primary Sjögren's syndrome (SS), rheumatoid arthritis (RA), chronic urticaria, and hepatitis C virus (HCV) infection were also examined. RESULTS: Expression of IFI16 was greatly increased and was ubiquitous in all layers of the epidermis and in the dermal inflammatory infiltrates of lesional skin from both patients with SLE and patients with SSc. Patients with SLE, those with primary SS, and those with SSc exhibited significantly higher anti-IFI16 IgG antibody levels compared with normal controls (for SLE, P < 0.002; for primary SS, P < 0.001; for SSc, P < 0.0005). Anti-IFI16 titers above the ninety-fifth percentile for control subjects were observed in 26% of the patients with SLE, 50% of those with primary SS, and 21% of those with SSc (28% of patients with limited cutaneous SSc [lcSSc] versus 4% of patients with diffuse cutaneous SSc [dcSSc]). In contrast, the prevalence of anti-IFI16 was 4% in patients with RA, 5% in those with chronic urticaria, and 13% in those with HCV infection. CONCLUSION: The results of this study provide evidence that an IFN-inducible gene, IFI16, may be involved in the pathophysiologic mechanisms of connective tissue disorders such as SSc. Moreover, a strict correlation with lcSSc was also demonstrated, thus providing a novel tool in the differential diagnosis of lcSSc from dcSSc. SN - 0004-3591 UR - https://www.unboundmedicine.com/medline/citation/17133607/A_novel_autoantigen_to_differentiate_limited_cutaneous_systemic_sclerosis_from_diffuse_cutaneous_systemic_sclerosis:_the_interferon_inducible_gene_IFI16_ L2 - https://doi.org/10.1002/art.22266 DB - PRIME DP - Unbound Medicine ER -